{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:10:56Z","timestamp":1790820656861,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Therapeutic antibodies (Abs) have been anticipated as promising alternatives to conventional treatments such as topical minoxidil and oral finasteride for androgenetic alopecia (AGA). Due to the high molecular weight of typical Abs, the half-life of subcutaneous Abs exceeds 2\u00a0weeks, allowing an administration intervals of once a month or longer. Direct injection into the areas of hair loss is also feasible, potentially enhancing treatment efficacy while minimizing systemic side effects. However, therapeutic Abs are rarely developed for AGA therapy due to the requirement to be responsiveness to androgens and to exist in the extracellular fluid or cell surface surrounding the hair follicle. In this review, we introduce recent progress of antibody therapeutics in AGA targeting the prolactin receptor, Interleukin-6 receptor, C-X-C motif chemokine ligand 12, and dickkopf 1. As therapeutic Abs for AGA are still in the early stages, targets need further validation and optimization for clinical application.<\/jats:p>","DOI":"10.3389\/fphar.2024.1434961","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:45:22Z","timestamp":1723769122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent approaches of antibody therapeutics in androgenetic alopecia"],"prefix":"10.3389","volume":"15","author":[{"given":"Su-Eon","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jino","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hyuk","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/IOCN2023-14546","article-title":"Nanotechnology-based Strategies for hair follicle Regeneration in androgenetic alopecia","volume":"14","author":"Ahmed Shaikh","year":"2023","journal-title":"Mater. Proc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40478-024-01730-1","article-title":"Interplay between androgen and CXCR4 chemokine signaling in myelin repair","volume":"12","author":"Asbelaoui","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"B3","volume-title":"HopeMed advances its androgenetic alopecia treatment to Phase II trials","author":"Barrie","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/ijms23031553","article-title":"The role of androgen receptor and microRNA interactions in androgen-dependent diseases","volume":"23","author":"Bielska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.5414\/CP202119","article-title":"A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers","volume":"52","author":"Caserini","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.tibtech.2022.12.020","article-title":"The booming business of hair loss","volume":"41","author":"Castro","year":"2023","journal-title":"Trends Biotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B72","volume-title":"Lymphatic transport of drugs","author":"Charman","year":"1992"},{"key":"B10","volume-title":"Chime Biologics and Hope medicine enter manufacturing agreement to speed up the launch of first-in-class antibody drug HMI-115 targeting endometriosis and androgenic alopecia","year":"2023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcjd.2016.03.004","article-title":"Testosterone and voluntary exercise promote angiogenesis in hearts of rats with diabetes by enhancing expression of VEGF-A and SDF-1a","volume":"40","author":"Chodari","year":"2016","journal-title":"Can. J. Diabetes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e13562","DOI":"10.1111\/cpr.13562","article-title":"Involvement of DKK1 secreted from adipose-derived stem cells in alopecia areata","volume":"57","author":"Choi","year":"2024","journal-title":"Cell Prolif."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1242\/jcs.02975","article-title":"The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis","volume":"119","author":"Christodoulides","year":"2006","journal-title":"J. Cell Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1172\/JCI99159","article-title":"Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation","volume":"128","author":"Clocchiatti","year":"2018","journal-title":"J. Clin. Invest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1677\/joe.1.06685","article-title":"Prolactin delays hair regrowth in mice","volume":"191","author":"Craven","year":"2006","journal-title":"J. Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","first-page":"332","article-title":"Prediction of immunogenicity for therapeutic proteins: state of the art","volume":"10","author":"De Groot","year":"2007","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/s41467-023-38039-x","article-title":"Engineering protein-based therapeutics through structural and chemical design","volume":"14","author":"Ebrahimi","year":"2023","journal-title":"Nat. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1046\/j.1523-1747.1999.00797.x","article-title":"Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number: implications for the control of hair follicle size and androgen responses","volume":"113","author":"Elliott","year":"1999","journal-title":"J. Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jocd.12171","article-title":"Assessment of tissue levels of dickkopf-1 in androgenetic alopecia and alopecia areata","volume":"15","author":"Fawzi","year":"2016","journal-title":"J. Cosmet. Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2353\/ajpath.2006.050468","article-title":"Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and\/or paracrine promoter of apoptosis-driven hair follicle regression","volume":"168","author":"Foitzik","year":"2006","journal-title":"Am. J. Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S0002-9440(10)64295-2","article-title":"Prolactin and its receptor are expressed in murine hair follicle epithelium, show hair cycle-dependent expression, and induce catagen","volume":"162","author":"Foitzik","year":"2003","journal-title":"Am. J. Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/protein\/gzx058","article-title":"Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy","volume":"30","author":"Goicochea","year":"2017","journal-title":"Protein Eng. Des. Sel."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.3390\/ijms21155342","article-title":"Hormonal effects on hair follicles","volume":"21","author":"Grymowicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00403-018-1853-5","article-title":"Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata","volume":"310","author":"Guttman-Yassky","year":"2018","journal-title":"Arch. Dermatol Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07144.x","article-title":"Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness","volume":"154","author":"Hamada","year":"2006","journal-title":"Br. J. Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins","volume":"106","author":"Hamuro","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/exd.14130","article-title":"Hormonal regulation in male androgenetic alopecia-Sex hormones and beyond: evidence from recent genetic studies","volume":"29","author":"Heilmann-Heimbach","year":"2020","journal-title":"Exp. Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e127474","DOI":"10.1172\/jci.insight.127474","article-title":"An effective cell-penetrating antibody delivery platform","volume":"4","author":"Herrmann","year":"2019","journal-title":"JCI Insight"},{"key":"B32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000184598","article-title":"Localisation of androgen receptors in dermal fibroblasts, grown in vitro, from normal subjects and from patients with androgen insensitivity syndrome","volume":"44","author":"Jacobson","year":"1995","journal-title":"Horm. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.xphs.2021.11.008","article-title":"Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo vadis?","volume":"111","author":"Jiskoot","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","article-title":"Is IL-6 a key cytokine target for therapy in COVID-19?","volume":"21","author":"Jones","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2147\/CCID.S385861","article-title":"Treatment of androgenetic alopecia: current guidance and unmet needs","volume":"16","author":"Kaiser","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/jid.2015.242","article-title":"The androgen receptor antagonizes wnt\/\u03b2-catenin signaling in epidermal stem cells","volume":"135","author":"Kretzschmar","year":"2015","journal-title":"J. Invest Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/jid.2011.274","article-title":"Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice","volume":"132","author":"Kwack","year":"2012","journal-title":"J. Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/sj.jid.5700999","article-title":"Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes","volume":"128","author":"Kwack","year":"2008","journal-title":"J. Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/jid.2009.340","article-title":"Mind the (gender) gap: does prolactin exert gender and\/or site-specific effects on the human hair follicle?","volume":"130","author":"Langan","year":"2010","journal-title":"J. Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1365-2133.2012.10856.x","article-title":"Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt\/\u03b2-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia","volume":"166","author":"Leiros","year":"2012","journal-title":"Br. J. Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/med.22011","article-title":"CXCR4\/CXCL12 axis: \"old\" pathway as \"novel\" target for anti-inflammatory drug discovery","volume":"44","author":"Lu","year":"2024","journal-title":"Med. Res. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4161\/derm.19472","article-title":"Hair loss and hyperprolactinemia in women","volume":"4","author":"Lutz","year":"2012","journal-title":"Dermatoendocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.56782\/pps.133","article-title":"Cytokine-targeted treatment in alopecia areata - new possibilities? prospects","volume":"21","author":"Maciej St\u0119pie\u0144","year":"2023","journal-title":"pps."},{"key":"B45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/DAD.0000000000001266","article-title":"Dickkopf-1 expression in androgenetic alopecia and alopecia areata in male patients","volume":"41","author":"Mahmoud","year":"2019","journal-title":"Am. J. Dermatopathol."},{"key":"B46","volume-title":"Prolactin receptor antibody for male and female pattern hair loss","author":"May","year":"2019"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/bjd.15577","article-title":"Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signalling pathways","volume":"177","author":"Michel","year":"2017","journal-title":"Br. J. Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jvc2.53","article-title":"The state-of-the-art in the management of androgenetic alopecia: a review of new therapies and treatment algorithms","volume":"1","author":"Miguel Dominguez-Santas","year":"2022","journal-title":"JEADV Clin. Pract."},{"key":"B49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1021\/acs.molpharmaceut.2c00510","article-title":"Efficacy of asymmetric siRNA targeting androgen receptors for the treatment of androgenetic alopecia","volume":"20","author":"Moon","year":"2023","journal-title":"Mol. Pharm."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ANTI.S33533","article-title":"Monoclonal antibodies for the prevention of rabies: theory and clinical practice","volume":"2014","author":"Nagarajan","year":"2014","journal-title":"Antib. Technol. J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1111\/jocd.14537","article-title":"Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics","volume":"20","author":"Nestor","year":"2021","journal-title":"J. Cosmet. Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/cosmetics10040106","article-title":"An updated etiology of hair loss and the new cosmeceutical paradigm in therapy: clearing \u2018the big eight strikes\u2019","volume":"10","author":"Nicholas Sadgrove","year":"2023","journal-title":"cosmetics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1210\/en.2015-1277","article-title":"A neutralizing prolactin receptor antibody whose in vivo application mimics the phenotype of female prolactin receptor-deficient mice","volume":"156","author":"Otto","year":"2015","journal-title":"Endocrinology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"B54","first-page":"371","article-title":"Hair loss: common causes and treatment","volume":"96","author":"Phillips","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"B55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P","article-title":"Lymphatic transport of proteins after subcutaneous administration","volume":"89","author":"Porter","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00403-018-1826-8","article-title":"Androgen modulation of Wnt\/\u03b2-catenin signaling in androgenetic alopecia","volume":"310","author":"Premanand","year":"2018","journal-title":"Arch. Dermatol Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1056\/NEJM199909233411307","article-title":"Treatment of hair loss","volume":"341","author":"Price","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: the therapeutic paradigm","volume":"34","author":"Renert-Yuval","year":"2017","journal-title":"Adv. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3934\/mbe.2021006","article-title":"Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes","volume":"18","author":"Salgado","year":"2020","journal-title":"Math. Biosci. Eng."},{"key":"B62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","article-title":"Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge","volume":"167","author":"Sanchez-Felix","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.3390\/molecules28186579","article-title":"Recent development of novel aminoethyl-substituted chalcones as potential drug candidates for the treatment of alzheimer's disease","volume":"28","author":"Sharma","year":"2023","journal-title":"Molecules"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Hum. Vaccin Immunother."},{"key":"B9","first-page":"155","article-title":"Vertex accentuation in female pattern hair loss in asians","volume":"68","author":"Supsrisunjai","year":"2016","journal-title":"Siriraj Med. J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/00003495-198937060-00004","article-title":"Muromonab CD3. A review of its pharmacology and therapeutic potential","volume":"37","author":"Todd","year":"1989","journal-title":"Drugs"},{"key":"B67","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pharma.2021.08.002","article-title":"Topical finasteride dose evaluation for treatment of androgenetic alopecia using computer simulations","volume":"80","author":"Todeschini","year":"2022","journal-title":"Ann. Pharm. Fr."},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-02636-2_3","article-title":"Inflammatory phenomena and fibrosis in androgenetic alopecia","volume-title":"Aging hair.","author":"Tr\u00fceb","year":"2010"},{"key":"B69","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaad.2019.09.013","article-title":"Pattern hair loss: assessment of inflammation and fibrosis on histologic sections","volume":"82","author":"Valdebran","year":"2020","journal-title":"J. Am. Acad. Dermatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jbspin.2013.07.002","article-title":"Hair-cycle changes in two patients taking tocilizumab","volume":"81","author":"Vidon","year":"2014","journal-title":"Jt. Bone Spine"},{"key":"B71","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000516300","article-title":"Hair growth in a patient with alopecia areata on tocilizumab","volume":"7","author":"Walker","year":"2021","journal-title":"Skin. Appendage Disord."},{"key":"B73","doi-asserted-by":"publisher","first-page":"122510","DOI":"10.1016\/j.ijpharm.2022.122510","article-title":"Approaches for estimating the clinical starting dose of new dosage forms: an example of a long-acting injectable formulation of finasteride","volume":"631","author":"Wook Kang","year":"2023","journal-title":"Int. J. Pharm."},{"key":"B74","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.arr.2022.101809","article-title":"CXCL12\/CXCR4: an amazing challenge and opportunity in the fight against fibrosis","volume":"83","author":"Wu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/cpt.2823","article-title":"Development of therapeutic proteins for a new subcutaneous route of administration after the establishment of intravenous dosages: a systematic review","volume":"113","author":"Xu","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/ijms25031705","article-title":"CXCL12 neutralizing antibody promotes hair growth in androgenic alopecia and alopecia areata","volume":"25","author":"Zheng","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"112996","DOI":"10.1016\/j.biopha.2022.112996","article-title":"CXCL12 inhibits hair growth through CXCR4","volume":"150","author":"Zheng","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B31","volume-title":"ADME and translational pharmacokinetics\/pharmacodynamics of therapeutic proteins: applications in drug discovery and development","author":"Zhou","year":"2015"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1434961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:45:32Z","timestamp":1723769132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1434961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":77,"alternative-id":["10.3389\/fphar.2024.1434961"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1434961","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"article-number":"1434961"}}